Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $100

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $95 to $100.

TD Cowen Maintains Buy on DexCom, Lowers Price Target to $75

TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $84 to $75.

Barclays Maintains Underweight on DexCom, Lowers Price Target to $67

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:DXCM) with a Underweight and lowers the price target from $72 to $67.

DexCom Q1 2026 Earnings Call Transcript

DexCom Affirms FY2026 Sales Guidance of $5.160B-$5.250B vs $5.230B Est

2026 Annual GuidanceDexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following

DexCom Q1 Adj. EPS $0.56 Beats $0.47 Estimate, Sales $1.191B Beat $1.175B Estimate

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.47 by 19.15 percent. This is a 75 percent increase over earnings of $0.32 per share from the same period

Earnings Scheduled For April 30, 2026

Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves

MiniMed shows improved pipeline and valuation upside as insulin pump adoption grows despite rising competition and past share losses.

GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech

GlucoTrack targets a Q2 2026 FDA IDE filing for CGM, backed by clinical data, manufacturing strategy, and reimbursement pathway.